These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2007-001174-81 RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB 2014-01-31 bad-data
Ongoing, reported early 2007-002115-59 CHIMIOTHERAPIE AVEC OU SANS ANTICOAGULATION PREVENTIVE DANS LES CANCERS DU PANCREAS METASTATIQUES not-yet-due
Ongoing, reported early 2007-002116-25 chimiothérapie d'induction par Erbitux-Taxotère-Cisplatine-5FU (ETPF) dans les carcinomes épidermoides de l'oropharynx de stade III-IV opérables not-yet-due
Not reported 2007-002797-56 Phase III study of an optimized chemotherapy + Avastin strategy +/- Tarceva in metastatic colorectal cancer. 2014-12-10 due-trials
Ongoing, reported early 2007-004806-28 An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemotherapy... not-yet-due
Exempt, with results 2008-005702-39 Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) not-yet-due
Ongoing 2009-010384-16 A Phase III randomized trial investigating the duration of adjuvant therapy with the modified FOLFOX 6 regimen (3 versus 6 months) for patients with stage III colon cancer. not-yet-due
Ongoing 2009-018058-44 Proof-of-concept phase II study to evaluate the anti-tumoractivity of sorafenib along with pathological and molecularchanges in tumor samples from patients with resectable hepatocellular carcinoma. not-yet-due
Ongoing 2012-001098-94 A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoid tumors not-yet-due
Completed, report not yet due 2013-001463-23 Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer. 2018-09-13 not-yet-due
Ongoing 2013-001928-19 Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study. not-yet-due
Ongoing 2017-002442-72 RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01 not-yet-due
Ongoing 2017-003185-27 A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squamou... not-yet-due